TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03277924
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT02495623
Drug: SYN-010 21 mg
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495623
Drug: SYN-010 42 mg
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02495623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02889523
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m²/dose, D1
Study: NCT02889523
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m²/dose, D1
Study: NCT02889523
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 in the morning D1 to D5
Study: NCT00360243
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02191241
Drug: Red Vine Leaf Extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01055808
Drug: Insulins
Normalized name: INSULINS AND ANALOGUES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose and frequency and duration as determined by the treating physician
Study: NCT00657852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
Study: NCT03806179
Drug: 10 MBq/kg Betalutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Study: NCT03806179
Drug: 15 MBq/kg Betalutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 MBq/kg Betalutin, lilotomab 40mg, rituximab 375 mg/m2
Study: NCT02076321
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
Study: NCT02076321
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
Study: NCT01153763
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
Study: NCT04263337
Drug: [11C] PiB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per study protocol static PET images will be acquired after IV infusion of CPiB to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT04263337
Drug: [18F] PBR111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per study protocol static PET images will be acquired after IV infusion of F-PBR111 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT02925104
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858272
Drug: H5.020CMV.PDGF-b and limb compression bandage
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03864016
Drug: Induction and maintenance of anesthesia
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
Study: NCT03864016
Drug: Adaptation of sufentanil doses according to the usual protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
Study: NCT03864016
Drug: Adjustment of sufentanil doses according to pupillometry
Approvals — FDA: no, EMA: no, PMDA: no
Description: At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
Study: NCT04081597
Drug: Star-101
Normalized name: STAR FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04081597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03340974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level
Study: NCT01474746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
Study: NCT03758716
Drug: FB825, FB825-15D11, Anti-CemX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: 20mg/ml solution Route of administration: IV
Study: NCT00633347
Drug: Antagonist GnRH Cetrotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrotide 0.25 mg. daily/ 7 days
Study: NCT01851330
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
Study: NCT00516152
Drug: Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day Preparative Regimen for GVHD Prophylaxis~* 7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~* 3 Fludarabine 30 mg/m(2)IV~* 2 REST Tacrolimus 0.01 mg/kg CIVI~* 1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~  * 1 Methotrexate 5mg/m(2)IV~ * 3 Methotrexate 5mg/m(2)IV~ * 6 Methotrexate 5mg/m(2)IV~ * 7 G-CSF 5mcg/kg SQ daily~ * 11 Methotrexate 5mg/m(2)IV~ * 90 Evaluate Response
Study: NCT03412799
Drug: SBP-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as subcutaneous (SC) injection, escalating dose cohorts
Study: NCT01420965
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose- Immune Enhancer
Study: NCT03474458
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline
Study: NCT03474458
Drug: Standard of care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy
Study: NCT02303821
Drug: Intrathecal (IT) Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02303821
Drug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02303821
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01243775
Drug: Belotaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 3 weekly (day 1)
Study: NCT01243775
Drug: Belloxa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/m2 3 weekly (day 2)
Study: NCT04271917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo oil to imitate CBD oil
Study: NCT04271917
Drug: acetaminophen 500mg and ibuprofen 200mg combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care
Study: NCT04195269
Drug: Test Article
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg CBD, 10 mg of THC, and a proprietary blend of terpenes.
Study: NCT04428684
Drug: Pepti 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient receives one injection of Pepti 3.6mg or Zoladex 3.6mg on Day 0 and a second injection of the same drug given the first time on Day 28. On Day 42 patients undergo endometrial ablation
Study: NCT00385008
Drug: Combination Product (sumatriptan succinate / naproxen sodium)
Normalized name: naproxen sodium / sumatriptan Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: sumatriptan/naproxen sodium
Study: NCT02470845
Drug: placebo patches of placebo-control group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm\*1cm round size.Each patch will be applied on one acupoint.
Study: NCT04032717
Drug: Q-Griffithsin (Q-GRFT) enema
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
Study: NCT03266939
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01766336
Drug: Group 1 ELND005
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01766336
Drug: Group 2 ELND005
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04182997
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients included in the placebo group will have their surgical site lavaged with sterile saline at the end of their surgery.
Study: NCT04059445
Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
Study: NCT00240630
Drug: sumatriptan succinate/naproxen sodium
Normalized name: sumatriptan succinate/naproxen sodium 10 mg-60 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Tablet of Treximet
Study: NCT00240630
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match
Study: NCT02279433
Drug: DS6051b
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-6051b 50 mg and 200 mg capsules for oral administration
Study: NCT03100123
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
Study: NCT00039702
Drug: [123] 5-I-A-85380
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01128179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo chewable tablets administered 3 times a day for 12 weeks
Study: NCT04679493
Drug: XC7 100 mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (1 capsule once, 100 mg)
Study: NCT04679493
Drug: XC7 200 mg single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (2 capsules once, 100 mg each)
Study: NCT04679493
Drug: Placebo single
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive a single dose of the ID (1 or 2 capsules once)
Study: NCT04679493
Drug: XC7 200 mg multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volunteers will receive multiple doses of the ID during 14 days (2 capsules daily, 100 mg each)
Study: NCT03903211
Drug: [18F]PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study: NCT02715570
Drug: PC945 - single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single doses
Study: NCT02715570
Drug: Placebo - single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single doses
Study: NCT02715570
Drug: Placebo - repeat doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT01499446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled twice daily (morning and evening) for 28 days
Study: NCT04335539
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care antibiotics will be selected by the investigator based on the suspected or confirmed pathogen(s) for the infection in accordance with local standards.
Study: NCT00962039
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
Study: NCT01187108
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 (or 2 in the placebo group) empty gel capsules
Study: NCT03352414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT01214746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet Unikalk 1 time pr day for 5 days
Study: NCT02227329
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic ELT will be administered at the time when the HPN is not being infused.
Study: NCT02227329
Drug: Heparin Lock
Normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mL of 100 U/ml heparin
Study: NCT02227329
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234858
Drug: (Hyzaar) losartan/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
Study: NCT00704509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated tablets, orally, 12 weeks
Study: NCT00000461
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000461
Drug: fatty acids, omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01388582
Drug: 30 mcg EE and 150 LNG oral contraceptive (Microvlar)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 women will receive oral contraceptive during breastfeeding
Study: NCT04136353
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 oral tablets twice daily for 96 weeks
Study: NCT00086281
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Solution
Study: NCT01724086
Drug: TMC647055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
Study: NCT02175901
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
Study: NCT03502434
Drug: SM04755
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
Study: NCT02645058
Drug: Intravenous pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: If required by the patient
Study: NCT02117167
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: m-TOR
Study: NCT02117167
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: FGFR
Study: NCT02117167
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: AKT
Study: NCT02117167
Drug: AZD8931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target: HER2, EGFR
Study: NCT02117167
Drug: Standard maintenance for squamous NSCLC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00437606
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40g po
Study: NCT01096849
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02850185
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
Study: NCT04194645
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT04194645
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution
Study: NCT02771470
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbial composition using probiotic
Study: NCT02771470
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota modulation using placebo
Study: NCT02793505
Drug: any drug not known as a major teratogen or major fetotoxicant
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is not an intervention but an observed exposure.
Study: NCT01716975
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1, 2
Study: NCT01716975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3
Study: NCT00751556
Drug: Naproxen Sodium 660mg
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release Naproxen Sodium (660mg) administered once a day
Study: NCT00751556
Drug: Commercial Aleve 220 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
Study: NCT01130597
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03571334
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
Study: NCT04335266
Drug: SHR2554
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR2554
Study: NCT02088684
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
Study: NCT02088684
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
Study: NCT02088684
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
Study: NCT02074579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo given 5g three times daily orally for 4 consecutive weeks
Study: NCT00123851
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01072539
Drug: tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As prescribed by physician in usual clinical practice
Study: NCT02474667
Drug: ANG-3777
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02317406
Drug: Biostime probiotics sachet children's formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostime probiotics sachet children's formula,1.5g Oral Single dose
Study: NCT04527354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo once a day during 4 weeks
Study: NCT01738451
Drug: GSK2118436 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
Study: NCT03571620
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Control
Study: NCT01738451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules will be administered in Part 2 of the study.
Study: NCT01546454
Drug: Ethinyl Estradiol-Levonorgestrel combination
Normalized name: ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
Study: NCT01546454
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.05 to 0.3 mg transdermal daily for 26 days
Study: NCT00952731
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo taken daily for 4-10 weeks.
Study: NCT00952731
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied to breasts daily for 4-10 weeks.
Study: NCT02167854
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02167854
Drug: LJM716
Approvals — FDA: no, EMA: no, PMDA: no